The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Advances in HER2-targeted therapies have improved the survival of patients with HER2-
positive breast cancer. The standard-of-care treatment for localized disease has been …

The last 25 years have seen significant growth in new therapeutic options for breast cancer,
termed targeted therapies based on their ability to block specific pathways known to drive …

Background A subcutaneous formulation of pertuzumab and trastuzumab with recombinant
human hyaluronidase in one ready-to-use, fixed-dose combination vial (pertuzumab …

Subcutaneous (SC) administration of monoclonal antibodies (mAbs) is a proven strategy for
improving therapeutic outcomes and patient compliance. The current FDA‐/EMA‐approved …

Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth
factor receptor 2 (HER2)-positive breast cancer and metastatic gastric cancer. Trastuzumab …

More oncology biologics are becoming available for subcutaneous (sc.) administration and
are expected to provide useful therapeutic options. We evaluated evidence published in the …

Human epidermal growth factor receptor type 2 (HER2) is a relevant and effective target in
breast cancer. The development of monoclonal antibodies against HER2 has revolutionized …

Approximately 20% of all breast cancers overexpress the human epidermal growth factor
receptor 2 (HER2). Targeting breast cancer through this vital oncogenic protein has been a …

Introduction The glycosaminoglycan hyaluronan forms a gel-like substance, which presents
a barrier to bulk fluid flow in the subcutaneous (SC) space, limiting SC drug delivery volume …